ArticlePhytomedicine : international journal of phytotherapy and phytopharmacology2017
Artemisia annua dried leaf tablets treated malaria resistant to ACT and i.v. artesunate: Case reports.
Article in Phytomedicine : international journal of phytotherapy and phytopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Phytochemical synergy in artemisia annua herbal tea against malaria: a systematic review of its efficacy and safety in the context of emerging Pfkelch13 resistance.Infectious diseases of poverty · 2026Pooled it
- Artemisia annua and Artemisia afra tea infusions vs. artesunate-amodiaquine (ASAQ) in treating Plasmodium falciparum malaria in a large scale, double blind, randomized clinical trial.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2019Trial
- Potential ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Recovery and Economic Aspects of Extraction Methods for Artemisinin and its Precursors fromACS omega · 2025Article
- Unlocking the potential of3 Biotech · 2025Review
- The plant matrix of Artemisia annua L. for the treatment of malaria: Pharmacodynamic and pharmacokinetic studies.PloS one · 2025Article
- From Traditional Use to Modern Evidence: The Medicinal Chemistry of Antimalarials from GenusMini reviews in medicinal chemistry · 2025Review
- Medicinal plants as more sustainable therapeutic solutions:Global health economics and sustainability · 2025Article
- Quest for malaria management using natural remedies.Frontiers in pharmacology · 2024Review
- Artemisinin as a therapeuticNatural product reports · 2023Review
- Diversity of bacterial community in the rhizosphere and bulk soil of Artemisia annua grown in highlands of Uganda.PloS one · 2023Article
- A phylogenetic perspective of antiviral species of the genusJournal of herbal medicine · 2022Article
- Review
- Towards greenhouse cultivation ofFrontiers in plant science · 2022Article
- Review
- A high-efficiency Agrobacterium-mediated transient expression system in the leaves of Artemisia annua L.Plant methods · 2021Article
- Contributions of the international plant science community to the fight against infectious diseases in humans-part 2: Affordable drugs in edible plants for endemic and re-emerging diseases.Plant biotechnology journal · 2021Review
- An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment.Journal of integrative medicine · 2021Review
- In vitro efficacy of artemisinin-based treatments against SARS-CoV-2.Scientific reports · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundDried leaf Artemisia annua (DLA) has shown efficacy against Plasmodium sp. in rodent studies and in small clinical trials. Rodent malaria also showed resiliency against the evolution of artemisinin drug resistance. PURPOSE: This is a case report of a last resort treatment of patients with severe malaria who were responding neither to artemisinin combination therapy (ACT) nor i.v. artesunate. STUDY
designOf many patients treated with ACTs and i.v. artesunate during the 6 mon study period, 18 did not respond and were subsequently treated with DLA Artemisia annua.
methodsPatients were given a dose of 0.5g DLA per os, twice daily for 5d. Total adult delivered dose of artemisinin was 55mg. Dose was reduced for body weight under 30kg. Clinical symptoms, e.g. fever, coma etc., and parasite levels in thick blood smears were tracked. Patients were declared cured and released from hospital when parasites were microscopically undetectable and clinical symptoms fully subsided.
resultsAll patients were previously treated with Coartem® provided through Santé Rurale (SANRU) and following the regimen prescribed by WHO. Of 18 ACT-resistant severe malaria cases compassionately treated with DLA, all fully recovered. Of the 18, this report details two pediatric cases.
conclusionsSuccessful treatment of all 18 ACT-resistant cases suggests that DLA should be rapidly incorporated into the antimalarial regimen for Africa and possibly wherever else ACT resistance has emerged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.